SpringWorks Therapeutics Announces Issuance of New U.S. Composition of Matter Patent to Polymorphic Form of Mirdametinib, Extending Patent Protection Into 2041
SpringWorks Therapeutics, Inc. - common stock (SWTX)
Last springworks therapeutics, inc. - common stock earnings: 3/12 04:30 pm
Check Earnings Report
Company Research
Source: GlobeNewswire
STAMFORD, Conn., July 20, 2021 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX) announced today that the United States Patent and Trademark Office (USPTO) has issued U.S. Patent No. 11,066,358 (the ‘358 patent), directed to mirdametinib, the Company’s product candidate in development for several oncology indications, including as a monotherapy for patients with neurofibromatosis type 1-associated plexiform neurofibromas (NF1-PN). The ‘358 patent, assigned to Warner-Lambert Company LLC (a subsidiary of Pfizer), expires in 2041. The ‘358 patent is a composition of matter patent that covers the polymorphic form of mirdametinib that is currently in clinical development. SpringWorks has exclusive rights to the ‘358 patent pursuant to an existing worldwide license with Pfizer. “We are very pleased that the USPTO has issued this patent, which extends patent protection for mirdametinib into 2041,” said Saqib Islam, Chief Executive Officer of SpringWorks. “This new patent i
Show less
Read more
Impact Snapshot
Event Time:
SWTX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
SWTX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
SWTX alerts
High impacting SpringWorks Therapeutics, Inc. - common stock news events
Weekly update
A roundup of the hottest topics
SWTX
News
- SpringWorks Therapeutics Announces Abstracts Accepted for Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting [Yahoo! Finance]Yahoo! Finance
- SpringWorks Therapeutics Announces Abstracts Accepted for Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual MeetingGlobeNewswire
- Global Desmoid Tumors Drug Pipeline Research Report 2024: Therapeutic Assessment by Product Type, Stage, Route of Administration, and Molecule Type [Yahoo! Finance]Yahoo! Finance
- SpringWorks Therapeutics: Multiple Opportunities, But No Sure-Fire Winners [Seeking Alpha]Seeking Alpha
- SpringWorks Therapeutics to Report First Quarter 2024 Financial Results Thursday, May 2, 2024 [Yahoo! Finance]Yahoo! Finance
SWTX
Earnings
- 11/2/23 - Beat
SWTX
Sec Filings
- 4/5/24 - Form ARS
- 4/5/24 - Form DEFA14A
- 4/5/24 - Form DEF
- SWTX's page on the SEC website